Nyxoah SA

Nyxoah SA reported strong Q2 2026 financial and operating results, with global net revenue reaching €7.7 million, a 21% sequential increase. U.S. net revenue grew 22% sequentially to €5.2 million, driven by continued commercial execution and a 100% prior authorization approval rate. The company secured $110 million in financing during the quarter, ending with €97.8 million in cash and equivalents. Nyxoah reaffirmed its full-year 2026 revenue guidance of €36 million to €40 million.

Nyxoah SA reported strong financial and operating results for Q2 and H1 2026, driven by U.S. commercial execution. Global net revenue for Q2 2026 reached €7.7 million, a 21% sequential increase, with U.S. net revenue growing 22% sequentially to €5.2 million. The company secured $110 million in financing during Q2, bolstering its cash position to €97.8 million. Operational highlights include significant increases in trained surgeons, activated accounts, and patients under prior authorization, alongside favorable reimbursement developments for its Genio system.

Nyxoah SA announced it will release its financial results for the second quarter of 2026 on Wednesday, August 5, 2026. Following the release, company management will host a conference call and webcast on the same day at 10:30pm CET / 4:30pm ET to discuss the results. Details for accessing the webcast and registering for the call to ask questions were provided.

Nyxoah SA announced preliminary unaudited second quarter 2026 results, with global net revenue expected to reach €7.7 million and U.S. net revenue at €5.2 million, both reflecting over 20% sequential growth. The company also highlighted positive proposed reimbursement increases from CMS for its Genio procedure, with hospital reimbursement potentially rising by 12% and ASC reimbursement by 15%. Nyxoah secured $110 million in new financing and reiterated its full-year 2026 revenue guidance of €36 million to €40 million.

Nyxoah SA announced the issuance of 146,531 new shares on June 30, 2026, resulting from the exercise of restricted share units. This update brings the total number of voting rights to 100,072,815 and the share capital to EUR 7,075,152.31. The company also provided details on outstanding subscription rights and convertible bonds, which could add 12,618,243 voting rights upon conversion.

Nyxoah SA announced transparency notifications regarding significant shareholding changes. Entities controlled by Orin Hirchman acquired 14,534,880 voting rights, representing 14.55% of the total shares, thereby crossing the 10% ownership threshold. Separately, Resmed Inc. passively decreased its stake to 1,943,828 voting rights, or 1.95% of the total shares, falling below the 3% threshold.

Nyxoah SA announced it received $15 million from the European Investment Bank, completing a total of $110 million in new capital raised in June 2026, including a recent equity offering. This non-dilutive debt funding will accelerate the US commercial launch of its Genio system, support R&D, and scale up manufacturing. Additionally, the company scheduled an extraordinary shareholders' meeting for July 9, 2026, to renew its authorized capital, and disclosed several transparency notifications regarding changes in major shareholdings.

Nyxoah SA announced it will host an Investor and Analyst Day on July 8, 2026, in New York. The event will feature the company's leadership team and Board discussing U.S. commercial execution, growth strategy, and key priorities for its Genio system. Key topics will include Genio U.S. launch momentum, market dynamics, reimbursement, and the company's path to profitability.

Nyxoah SA announced it received $15 million from the European Investment Bank (EIB), representing the second tranche of its loan facility. This non-dilutive debt funding, combined with a recent equity raise, brings the total capital raised in June 2026 to $110 million. The proceeds are primarily intended to accelerate the commercial launch of the Genio system in the United States, support research and development, and scale up manufacturing. CEO Olivier Taelman stated this financing completes a transformative period for the company, positioning it strongly for its next growth phase.

Nyxoah SA announced that its Genio® hypoglossal nerve stimulation therapy for Obstructive Sleep Apnea (OSA) received the prestigious Prix Galien UK 2026 Award for Best Medical Technology. This award is a significant recognition of Genio's impact on patient care and outcomes. The company highlighted recent business momentum, including FDA approval and commercial launch in the U.S., new financing to accelerate U.S. expansion, and increasing adoption across Europe and other international markets.